Who is sponsoring NCT06162611?

NCT06162611 is sponsored by Lori Gawron.

What condition does NCT06162611 study?

NCT06162611 studies Emergency Contraception.

Is NCT06162611 still recruiting?

NCT06162611 is currently recruiting now. Last updated 24 April 2025.

Last reviewed 2025-04-24 · How we verify

NCT06162611

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo

Recruiting now Phase 4 Last updated 24 April 2025

What this trial tests

Phase 4 trial testing Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg in Emergency Contraception in 790 participants. Currently enrolling.

Timeline

6 November 2023

Primary endpoint
30 April 2028

31 May 2028

Quick facts

Lead sponsor	Lori Gawron
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	790
Start date	6 November 2023
Primary completion	30 April 2028
Estimated completion	31 May 2028
Sites	1 location across United States

Drugs / interventions tested

Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg — full drug profile →
Etonogestrel implant with oral placebo

Conditions studied

Emergency Contraception — all drugs for Emergency Contraception →

Sponsor

Lori Gawron — full company profile →

Who can join

Adults 18 to 35, female only, with Emergency Contraception. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intrauterine devices (IUDs) are highly effective to prevent pregnancy when used for emergency contraception (following unprotected intercourse in the last 3 days), but data are lacking for people who desire an etonogestrel (ENG) contraceptive implant in this situation. This proposal will identify the most effective way to start an implant for emergency contraception using a randomized controlled trial comparing pregnancy risk between those receiving the implant vs. the implant plus oral emergency contraception (EC). Data from this project will inform clinical practice and add another option, the implant, for those desiring a long acting, highly effective contraceptive method when they present for emergency contraception.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacodynamic evaluation of the etonogestrel contraceptive implant initiated midcycle with and without ulipristal acetate: An exploratory study.
Gawron LM, Kaiser JE, Gero A, Sanders JN, et al · · 2024 · cited 1× · PMID 38232940 · DOI 10.1016/j.contraception.2024.110370

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06162611 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lori Gawron
Last refreshed: 24 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06162611.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing